homepage-top-section

The approval enables to use of Kynmobi sublingual film for the acute and intermittent treatment of off episodes in patients with Parkinson’s disease. Kynmobi, a novel formulation of

Octagam 10% is an immune globulin intravenous (human) liquid preparation designated to treat chronic immune thrombocytopenic purpura (ITP) in adults. According to the company, the primary objective of

The approval allows Zolgensma to treat patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1or patients with

Earlier this month, the FDA has completed its review of Moderna’s investigational new drug (IND) application for mRNA-1273 to conduct Phase 2 study, which is expected to be

The company has secured approval from the Drugs Controller General of India (DCGI) to begin the trial with Favipiravir at the end of April. Favipiravir is a generic

Based in South San Francisco of California, Portola is engaged in the discovery, development and commercialisation of novel therapeutics for thrombosis and other haematologic conditions. The company’s commercialised

Junshi Biosciences, a Chinese biopharmaceutical company, is working to discover therapies to combat Covid-19 from the starting of the outbreak. The company has designed multiple neutralising antibodies and

The Government of Canada has granted the funds under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support the discovery of antibodies for use in

The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people